Clinical Trials
The following is a guide to learn more about a number of clinical trials that are taking place at pharmaceutical and medical device companies who are a part of HOPA’s Industry Relations Council (IRC).
To learn more about all active clinical trials, please visit clinicaltrials.gov.
IRC Partner Clinical Trials Listings
- Abbvie
- AstraZeneca
- Beigene
- Daiichi Sankyo
- Exelixis
- Genentech
- Genmab
- Incyte
- Iovance
- Iovance Clinical Trials
- Iovance: Solid Tumor Trial – NCT03645928 – A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
- Iovance: Cervical Cancer - NCT03108495 - A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma
- Iovance: NSCLC – LUN-202 - A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Metastatic Non-Small-Cell Lung
- Iovance Lung Therapy: A Phase 2 Clinical Study for Metastatic Non-Small Cell Lung Cancer (NSCLC) LUN-202 is a Phase 2, multicenter clinical trial for patients whose current chemoimmunotherapy for NSCLC has stopped working.
- Iovance Clinical Trials
- Jazz
- Johnson & Johnson
- J&J: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)
- J&J: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)
- J&J: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-3)
- J&J: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)
- Lilly
- Merck
- Regeneron
- Sanofi
- Servier
- Stemline Therapeutics
- Stemline Therapeutics Clinical Trials
- A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
- ELEGANT- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- ELEVATE – Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
- ELECTRA – Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer
- ELCIN – ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
- SUMIT-ELA-A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
- ADELA - Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i
- Stemline Therapeutics Clinical Trials
- AbbVie Science Clinical Trials
- AstraZeneca Clinical Trials
- Beigene Clinical Trials
- Daiichi Sankyo Clinical Trials
- Exelixis Clinical Trials
- Genentech Clinical Trials
- Incyte Clinical Trials
- Iovance Clinical Trials
- Lilly Clinical Trials
- Merck Clinical Trials
- Regeneron Clinical Trials
- Sanofi Clinical Trials
- Servier Clinical Trials
- Stemline Therapeutics Clinical Trials
- Taiho Oncology’s Clinical Trials
- Zanidatamab Oncology Clinical Trials
- ELEGANT- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- ELEVATE – Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
- ELECTRA – Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer
- ELCIN – ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
- SUMIT-ELA-A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
- ADELA - Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i
- Zanidatamab Oncology Clinical Trials
- Iovance: NSCLC – LUN-202 - A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Metastatic Non-Small-Cell Lung
- Iovance Lung Therapy: A Phase 2 Clinical Study for Metastatic Non-Small Cell Lung Cancer (NSCLC) LUN-202 is a Phase 2, multicenter clinical trial for patients whose current chemoimmunotherapy for NSCLC has stopped working.
- Iovance: Solid Tumor Trial – NCT03645928 – A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
- Sanofi Clinical Trials
- J&J: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)
- J&J: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)
- J&J: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-3)
- J&J: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)
